Formulary
Efgartigimod alfa: Indications, Dosing, Side Effects and Interactions
Efgartigimod alfa is a human recombinant immunoglobulin G1 (IgG1) antibody fragment that binds to the neonatal Fc receptor (FcRn), thereby reducing the levels...
MedNext Academy | 3 min read
Efgartigimod alfa: Indications, Dosing, Side Effects and Interactions
Efgartigimod alfa is a human recombinant immunoglobulin G1 (IgG1) antibody fragment that binds to the neonatal Fc receptor (FcRn), thereby reducing the levels...
Drug action
Efgartigimod alfa is a human recombinant immunoglobulin G1 (IgG1) antibody fragment that binds to the neonatal Fc receptor (FcRn), thereby reducing the levels of circulating IgG, including pathogenic IgG autoantibodies, and improving neuromuscular transmission.
Indications and dose
**Myasthenia gravis (under expert supervision)**
- **Adult** (By Intravenous Infusion): 10 mg/kg once weekly (max. per dose 1.2 g) for 4 weeks, subsequent 4-week cycles to be administered, according to response, at least 7 weeks from the start of the previous cycle, for advice on missed doses-consult product literature.
Cautions
Active infections; administration of vaccinations Cautions, further information Vaccination Administer vaccinations at least 4 weeks before starting treatment. If vaccinations are required during treatment, administer them at least 2 weeks after the last infusion of a treatment cycle and 4 weeks before starting the next cycle-immunisation with vaccines during treatment has not been studied. Live or live attenuated vaccines should be avoided during treatment-safety is unknown. M
Side effects
Common or very common Increased risk of infection; myalgia; procedural headache
Pregnancy
Use only if potential benefit outweighs risk (no information available). M
Breast feeding
Specialist sources indicate use with caution (no information available). Large molecular weight suggests limited excretion into milk and drug molecule likely to be partially destroyed in the infant's gastro-intestinal tract.
Medicinal forms
Clinical governance
**Author:** MedNext Clinical Team. **Clinical reviewer:** Dr Shameer Deen, MBBS, MS, MRCS. **Sources:** BNF, Indian Pharmacopoeia, CIMS India. **Correction:** Report errors at support@mednext.academy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
FormularyBrowse all drugs
Search 1,850+ drug profiles.
Study Efgartigimod alfa in the MedNext app
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary

